Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wedbush reissued their outperform rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $52.00 price objective on the stock. Wedbush also issued estimates for Replimune Group’s Q3 2024 earnings at ($0.90) EPS, FY2024 earnings at ($3.57) EPS, FY2025 earnings […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $13.34 and last traded at $13.34, with a volume of 529686 shares traded. The stock had previously closed at $14.29. Analyst Ratings Changes Separately, HC Wainwright reduced their price objective on […]
Oncolytic Adenovirus MarketDuring the forecast period 2023 to 2033, the oncolytic adenovirus market is expected to grow at a value of 7.5% CAGR, according to Future Market Insights. By the year 2033, the global market for oncolytic adenovirus is expected to rise up to a market valuation of US$ 250 Billion. Growth of...
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $15.33 and last traded at $15.41, with a volume of 25155 shares traded. The stock had previously closed at $16.17. Analyst Ratings Changes Separately, HC Wainwright dropped their target […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 2,604 put options on the company. This represents an increase of 110% compared to the average volume of 1,239 put options. Replimune Group Stock Performance REPL traded down $0.25 during trading on Wednesday, hitting […]